Press releases

Company updates third quarter financial results and full-year 2009 guidance

Third-generation drug-eluting stent now available in CE Mark countries

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...

Company to webcast its conference call on October 20. Learn how to tune in

Three models of stenting system now available for palliative treatment of malignant common bile duct strictures

Study to determine which device programming strategy best minimizes the occurrence of unnecessary therapy in ICD and CRT-D patients

Agreement will settle more than a dozen lawsuits involving intellectual property in the interventional cardiology arena

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Results support benefits of paclitaxel-eluting stents in diabetic patients

Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent

Both drug-eluting stents performed well in diabetic patients

Intravascular Ultrasound (IVUS) technology designed to provide physicians a 360-degree view inside the heart and coronary vessels

PLATINUM clinical program to support FDA approval of PROMUS® Element™ Stent

Scientific symposium presentations to include clinical data on TAXUS and PROMUS stents

Agreement promotes access to testing solutions for female urinary incontinence

A live webcast and replay of the September 15 healthcare conference will be available.

A live webcast and replay of the September 9 session will be available.

Findings provide additional support for PCI as a viable treatment option for patients with complex coronary anatomy

The mortality reduction trend was also observed in high-risk patients with severely reduced heart function

Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC

Dr. Ken Stein to join CRM group

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European...

Statement from Pete Nicholas, Chairman of the Board, pays tribute to Sen. Kennedy's dedication to providing access to quality health care

Final results from the MADIT-CRT trial will be presented on Tuesday, September 1

A live webcast and replay of the August 5 session will be available.

Election of Bartlett and Byrnes increases the Boston Scientific Board to 13 members

"We delivered sales and earnings at the high end of our guidance range,” Ray Elliott, President and CEO

Longest available drug-eluting stent strengthens Company's broad portfolio

System remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status

Learn how to tune in or find the replay of the July 21 conference call

“We are confident Ray offers the right combination of experience, results and talents for Boston Scientific going forward,” said board chairman Pete Nicholas

Landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure in asymptomatic and mildly symptomatic patients NATICK, Mass., June 23 /PRNewswire-FirstCall/ -- Boston...

A live webcast and replay of the June 24th conference session will be available.

Presentations to feature results on pelvic floor reconstruction systems and mid-urethral sling systems

Studies to be presented on safety and efficacy of SpyGlass System for diagnostic and therapeutic procedures throughout pancreatico-biliary system NATICK, Mass., May 28 /PRNewswire-FirstCall/ --...

SpyGlass® Direct Visualization System can now be used for diagnostic and therapeutic procedures for pancreatic disease NATICK, Mass., May 28 /PRNewswire-FirstCall/ -- Boston Scientific...

"We are grateful for their service to Boston Scientific and its customers, patients and shareholders," said Pete Nicholas, Chairman of the Board

Specifically designed for treating small coronary vessels; joins the TAXUS® Express® Atom™ Stent as the only drug-eluting stents approved for small vessel use in the U.S.

Risk of death at five years is lower for aneurysm patients treated with coil embolization compared to surgical clipping

ORION clinical trial to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of economic and quality of life outcomes,...

Boston Scientific Corporation (NYSE: BSX) today announced that Fitch Ratings has raised the Company's rating outlook to positive from stable, while...

Results support previously announced outcomes with PCI and CABG in patients with left main coronary disease

TAXUS® Element™ Drug-Eluting Stent is now available in select markets worldwide

Online tools will help physicians determine treatment strategies

A live webcast and replay of the May 22 conference will be available.

Presentations to include additional analyses from the landmark SYNTAX trial

ALTITUDE analysis presented at the Heart Rhythm Society Scientific Sessions

Analysis indicates that one life is now saved for every six patients who receive an ICD

Donation marks the beginning of Company's agreement to provide the non-profit organization with CRM devices that would otherwise remain unused